Swiss Banks Stock News

Nestlé has recalled multiple batches of its SMA baby formula after regulators confirmed contamination with the food poisoning toxin cereulide traced to a shared third-party ingredient supplier, prompting investigations in France into possible links with two infant deaths. Beyond the immediate product recall, the episode highlights how dependence on external suppliers can expose even large food companies to heightened operational and reputational risk. We will now examine how these food...

What UBS Group’s recent performance data tells you UBS Group (SWX:UBSG) has drawn investor attention after a mixed spell, with a small 1 day decline and a negative move over the past week, while the past 3 months show a positive total return. Over the past year, UBS Group’s total return stands at 16.6%, with a 3 year total return around 2x and a 5 year total return a little over 3x. This highlights a longer term recovery profile for shareholders. See our latest analysis for UBS Group. Recent...

Adecco Group (SWX:ADEN) has agreed to acquire Advantis Medical Staffing. The deal expands Adecco’s presence in North American healthcare staffing. Advantis adds travel nursing and allied health capabilities to Adecco’s portfolio. The acquisition focuses Adecco more on healthcare as a critical talent segment. Adecco Group, a global provider of HR and workforce solutions, is deepening its focus on healthcare staffing through the purchase of Advantis Medical Staffing. Advantis brings a...

Why ABB’s latest earnings and AI exposure matter now ABB (SWX:ABBN) has jumped onto many watchlists after reporting fourth quarter 2025 results ahead of forecasts, winning more than US$10b in new orders, and highlighting benefits from rising AI driven data centre demand. See our latest analysis for ABB. The 8.46% 1 day share price return and 11.56% 7 day share price return at CHF66.38 suggest momentum has picked up quickly around the earnings beat and new US$2b buyback. At the same time, the...

Roche Holding AG recently reported 2025 results showing sales of CHF 61,516 million and net income of CHF 12,880 million, while also advancing its obesity pipeline with strong Phase II data for CT-388 indicating significant placebo-adjusted weight loss and a generally tolerable safety profile. Alongside proposing a higher CHF 9.80 dividend for what would be a 39th consecutive increase, Roche issued 2026 guidance for mid single digit Group sales growth and high single digit core EPS growth at...

EPIC Suisse's (VTX:EPIC) stock up by 6.2% over the past three months. However, its weak financial performance...

Key Insights Significant control over Mobimo Holding by retail investors implies that the general public has more power...

The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But if you buy shares in a...

It is hard to get excited after looking at Burckhardt Compression Holding's (VTX:BCHN) recent performance, when its...

A lackluster earnings announcement from Bergbahnen Engelberg-Trübsee-Titlis AG ( VTX:TIBN ) last week didn't sink the...

Shareholders might have noticed that Logitech International S.A. ( VTX:LOGN ) filed its third-quarter result this time...

It's not a stretch to say that OC Oerlikon Corporation AG's ( VTX:OERL ) price-to-sales (or "P/S") ratio of 0.5x right...

March ICE London cocoa prices recently hit a 2.25 year low as supplies increased and demand softened, while Barry Callebaut (SWX:BARN) reported a 22% sales volume decline in its cocoa division for the latest quarter. See our latest analysis for Barry Callebaut. The cocoa volume drop and softer market backdrop sit against a share price that has risen 22.85% over the past 90 days and a 1 year total shareholder return of 32.74%, although the 3 and 5 year total shareholder returns remain...

Key Insights The projected fair value for Swisscom is CHF938 based on 2 Stage Free Cash Flow to Equity Swisscom's...

Idorsia (SWX:IDIA) has been drawing attention after a mixed set of recent returns. The stock is down about 17% over the past month but up roughly 10% over the past 3 months. See our latest analysis for Idorsia. At a share price of CHF3.645, Idorsia is coming off a 1 day share price return of about a 1% decline and a 30 day share price return of roughly a 17% decline. Its 1 year total shareholder return is very large, while the 3 and 5 year total shareholder returns remain deeply negative...

As the European markets navigate renewed trade and geopolitical uncertainties, with major indices like France's CAC 40 and Germany's DAX experiencing declines, investors are increasingly focused on identifying opportunities within this challenging environment. Amidst these fluctuations, finding undervalued stocks can be a strategic approach to potentially benefit from market inefficiencies and capitalize on businesses that may not fully reflect their intrinsic value due to current market...

In January 2026, BD (Becton, Dickinson and Company) and Ypsomed Holding AG expanded their partnership to develop a 5.5 mL BD Neopak XtraFlow Glass Prefillable Syringe fully compatible with Ypsomed’s YpsoMate 5.5 autoinjector platform, targeting large-volume subcutaneous biologic injections. This move highlights how device and syringe co-development can help pharmaceutical companies address rising drug volumes and viscosities while aiming to shorten combination-product development...

In January 2026, HIAG Immobilien Holding AG announced that it expects consolidated net profit for 2025 to be 50% to 55% higher than the 2024 figure of CHF 75.2 million, meaning earnings should clearly exceed both last year’s result and prior market expectations. A few days earlier, the company had successfully placed a CHF 100 million green bond with a seven-year term and a 1.34% coupon, extending its average financing maturity while earmarking proceeds for sustainable buildings and projects...

As European markets navigate renewed trade and geopolitical uncertainty, with the pan-European STOXX Europe 600 Index ending 0.98% lower, investors are keenly observing high-growth tech stocks that could potentially thrive in this environment. In such a climate, a good stock is often characterized by its ability to adapt to changing market conditions and leverage technological advancements to maintain robust growth trajectories amidst broader economic challenges.

While some investors are already well versed in financial metrics (hat tip), this article is for those who would like...

Logitech International (SWX:LOGN) has put up a solid Q3 2026 scorecard, with revenue of about US$1.4b and basic EPS of US$1.71 anchoring its latest quarterly update. The company has seen quarterly revenue move from US$1.01b in Q4 2025 to US$1.42b in Q3 2026, while basic EPS has ranged from roughly US$0.97 to US$1.71 over the same stretch. This gives you a clear sense of how the top and bottom line have tracked together. With trailing 12 month net profit margin sitting near the mid teens and...

What the new contracts mean for Implenia stock Implenia (SWX:IMPN) has secured around €350 million of new bridge and tunnel projects in Germany and Norway, all tied to motorway links, mobility infrastructure and energy supply related transport corridors. For you as an investor, these contracts extend Implenia’s visibility on large, complex work across several years. Projects such as the Peene bridge, the Markbreit bridge replacement and the Riederwald tunnel form a sizeable order...

Nestlé (SWX:NESN) has recalled specific batches of baby formula after reports of contamination with the toxin cereulide. French authorities are investigating two infant deaths that may be linked to the recalled formula. National regulators have issued consumer warnings while inquiries into product safety and quality controls continue. Nestlé, listed as SWX:NESN, is a major global food and beverage group with a large presence in infant nutrition. When a core product such as baby formula is...

In recent trading, Bachem Holding drew strong attention after reports of new commercial NCE contracts, improved operating cash flow and better capacity utilization highlighted progress in its operations. These developments are being interpreted as potentially supporting a richer valuation multiple, even as some models flag risks and emphasize upcoming earnings and contract updates as key signposts. Next, we will examine how Bachem’s improved operating cash flow shapes its broader investment...